SHANGHAI, China and PALO ALTO, Calif., April 20, 2015 (GLOBE NEWSWIRE) -- Cellular Biomedicine Group Inc. (Nasdaq:CBMG) ("CBMG" or the "Company"), a biomedicine firm engaged in the development of effective treatments for degenerative and cancerous diseases, today announced that the Company has engaged Huntsworth Health, a global healthcare marketing and communications agency to build a global KOL advocacy campaign for CBMG's ReJoinTM human adipose-derived mesenchymal progenitor cell (haMPC) clinical trials for the treatment of Knee Osteoarthritis.
"We are pleased to work with Huntsworth Health, who is uniquely positioned to identify, profile and target KOLs and medical investigators for our Knee Osteoarthritis ReJoinTM clinical trials through their experienced team of international medical professionals and build a campaign that will resonate with our key stakeholders," commented Dr. William (Wei) Cao, Chief Executive Officer of Cellular Biomedicine Group. "We recognize the significance of having our clinical data validated by global thought leaders who have meaningful influence in the social, economic, medical, strategic and investment communities. We look forward to broadening our communications and building support as we expect to release full year Phase IIb clinical data on ReJoinTM in the fourth quarter of 2015."
About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers. Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility in China, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards. To learn more about CBMG, please visit: www.cellbiomedgroup.com
About Huntsworth Health
Huntsworth Health is a global healthcare marketing and communications agency with seventy wholly owned offices in thirty countries, over two hundred healthcare consultants, of which, over seventy possesses advanced medical and scientific degrees. Through its health and scientific focus, Huntsworth Health deploys unmatched scientific knowledge and complete B2B and B2C capabilities in the continuum from science to health and wellness.
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.
CONTACT: Sarah Kelly Director of Corporate Communications, CBMG +1 650 566-5064 firstname.lastname@example.org Vivian Chen Managing Director Investor Relations, Grayling +1 347 481-3711 email@example.com
Source:Cellular Biomedicine Group Inc.